The present specification relates to a compound of Chemical Formula 1 and an organic electronic device comprising the same.

A thin film semiconductor comprising a compound of formula I or II wherein: R.sup.1 and R.sup.2, at each occurrence, independently are selected from a C.sub.1-30 alkyl group, a C.sub.2-30 alkenyl group, a C.sub.2-30 alkynyl group and a C.sub.1-30 haloalkyl group, R.sup.3, R.sup.4, R.sup.5, and R.sup.6 independently are H or an electron-withdrawing group, wherein at least one of R.sup.3, R.sup.4, R.sup.5, and R.sup.6 is an electron-withdrawing group; and a non-conductive polymer. ##STR00001##

The present disclosure relates to certain AHR agonist compounds, their method of making, and to pharmaceutical compositions comprising the compounds and to methods of using the compounds to treat immune-mediated diseases, such as psoriasis and atopic dermatitis.

Compounds of formula (I): ##STR00001##
wherein R.sub.a, R.sub.b, R.sub.c, R.sub.d, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, X, Y and Het are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

Compounds of formula (I): ##STR00001##
wherein R.sub.a, R.sub.b, R.sub.c, R.sub.d, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, X, Y and Het are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Antibodies which selectively bind to complexes of such compounds with TNF superfamily members are disclosed. These antibodies may be used to detect further compounds with the same activity, and as target engagement biomarker.

It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Antibodies which selectively bind to complexes of such compounds with TNF superfamily members are disclosed. These antibodies may be used to detect further compounds with the same activity, and as target engagement biomarker.

The present disclosure relates generally to novel molecules, compositions, and formulations for treatment of bacterial infections in general and more specifically to bacterial infections with antibiotic resistant pathogens.

The aspects of the disclosed embodiments are directed to novel compounds, specifically, quaternary ammonium derivatives of tertiary amine containing opioid drug compounds such as hydrocodone, hydromorphone and oxycodone, formulations containing said. compounds or pharmaceutically acceptable salts thereof, which are capable of providing controlled release of the opioid drug upon administration to a patient in order to treat pain.

Compositions are disclosed herein that include macrocycle derivatives incorporating bridged macrocycles. Also disclosed are methods of producing and using the compositions.